Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOLTO: Venetoclax, Atezolizumab, and Obinutuzumab for Richter Transformation
NCT04082897Phase 2Active, not recruiting
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Oct 2019
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax, atezolizumab, obinutuzumab in Richter's syndrome (RS), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Started Oct 2019; status: active, not recruiting.
02
Drugs
venetoclaxatezolizumabobinutuzumab
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT04082897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082897.